1. Home
  2. FUBO vs GLUE Comparison

FUBO vs GLUE Comparison

Compare FUBO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo fuboTV Inc.

FUBO

fuboTV Inc.

HOLD

Current Price

$2.60

Market Cap

928.8M

Sector

Industrials

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$23.85

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUBO
GLUE
Founded
2009
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
928.8M
1.1B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
FUBO
GLUE
Price
$2.60
$23.85
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$5.35
$27.00
AVG Volume (30 Days)
10.2M
2.8M
Earning Date
02-27-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.34
0.25
Revenue
$1,616,726,000.00
$181,538,000.00
Revenue This Year
N/A
$84.02
Revenue Next Year
$4.68
N/A
P/E Ratio
$7.76
$93.97
Revenue Growth
1.70
1112.27
52 Week Low
$2.28
$3.50
52 Week High
$4.90
$25.77

Technical Indicators

Market Signals
Indicator
FUBO
GLUE
Relative Strength Index (RSI) 41.57 69.04
Support Level $2.45 $23.19
Resistance Level $2.70 $25.77
Average True Range (ATR) 0.11 1.52
MACD 0.03 0.81
Stochastic Oscillator 61.40 83.77

Price Performance

Historical Comparison
FUBO
GLUE

About FUBO fuboTV Inc.

FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: